Anupam Datta, Sr. Consultant Radiation Oncologist at NCRI Hospital, Kolkata, shared on LinkedIn:
“Honored to present my 4th IASLC-affiliated study at NACLC 2025 in Chicago. Our poster focused on a question that’s deeply relevant to LMICs like India.
“Can Afatinib serve as a cost-effective first-line option for patients with EGFR exon 19 deletion and L858R mutation when Osimertinib is financially out of reach?”
Our real-world findings add one more piece to that conversation.
Another memorable moment from the meeting:
Finally meeting Chiaojung Jillian Tsai , whose CURB trial has been instrumental in shaping radiation strategies for oligo-progressive lung cancer. Inspiring work, and even more inspiring in person.
Always grateful for opportunities to present, learn, and connect with colleagues advancing lung cancer care across the world.”
More posts featuring Anupam Datta on OncoDaily.
